01
Deploy in a week, not a quarter.
No multi-suite procurement. One trial, one upload, sites onboarded by invite link.
Trial document intelligence
Every protocol question, answered from the source.
Sponsors upload protocols, lab manuals, and pharmacy manuals. Coordinators, principal investigators, and CRAs ask in plain English. Every answer cites the page and shows the highlighted passage in the source PDF, right next to the answer.
JM
J. Mendez, CRC, ATD002
Question
Can a patient on bimekizumab enroll?
Sponsor verifiedp. 52
No. Section 5.2 lists biologic IL-17 inhibitors as exclusionary if dosed within 12 weeks of screening. Bimekizumab is an IL-17A/F inhibitor and falls under that exclusion. A 12-week washout is required before re-screening.
Protocol_v3.2.pdf52 / 218
02 / What's at stake
What an unanswered question actually costs.
$55,716
Direct cost of one delay day in a Phase III trial.
Source: Tufts CSDD, Day of Delay white paper, August 2024.
76%
Of trial protocols now require at least one substantial amendment. Up from 57% in 2015.
Source: Tufts CSDD, 2024.
33–45%
Of substantial protocol amendments are avoidable.
Source: Tufts CSDD via Getz et al.
The $35,000-per-day figure that ran in industry decks for two decades was a 1990s estimate. The current direct cost of a Phase III delay is $55,716 a day, on top of roughly $500,000 a day in unrealized prescription drug sales. A trial that lands twelve weeks late costs the sponsor about $46 million.
The questions that drive that delay arrive months earlier. They sit in coordinator inboxes, on Friday-afternoon CRA calls, and in chat threads no one searches. Most are scattered. Most are unanswered. One in three of the resulting amendments could have been avoided if those signals had been captured as structured data the first time the question came up. That capture is what AskMyTrials does.
03 / Why us
Built for pilots, not platforms.
Most clinical-trial software ships as a multi-year enterprise suite. Procurement, validation, and rollout outlast the trial itself. AskMyTrials does one thing well, and ships in a week.
02
Cite the page. Show the passage.
Every answer points to the exact page in the sponsor's approved document, and renders the highlighted passage inline next to the answer. No paraphrase. No hallucination. The reader verifies the answer against the source without leaving the screen.
03
Confusion is structured data.
The same question asked across thirty sites is the next protocol amendment, sitting in your dashboard before the timeline cost lands.
04 / Product
Three sides, one source of truth.
For sponsors
- Upload protocol, lab manual, and pharmacy manual per trial. Approve which versions are searchable.
- See where confusion is concentrated, by trial, by section, by site. Watch which sites are engaged and which have gone silent.
- Review the questions sites ask most often. Edit a canonical answer. Mark it sponsor-verified, and sites see a “Sponsor verified” badge on that answer from then on.
- Export Amendment Brief PDFs and full TMF-ready Q&A bundles. Cover page, per-question PDFs, audit log, and SHA-256 manifests, built to drop into a regulatory submission.
- Compare against peer trials when five or more peer trials are in the cohort, or against published industry benchmarks (Tufts, TransCelerate) when they aren't. Generate a quarterly ROI PDF: deviations likely prevented, coordinator hours saved, and dollar value.
askmytrials.com/dashboard/analytics
1,284
Questions, 30d
37
Sites engaged
9
Clusters surfaced
Confusion clusters by section
5.2 Exclusion
214
7.4 Dosing
172
9.1 Lab manual
134
11.3 SAE
96
6.8 Pharmacy
64
For sites
- One login across every sponsor's trial you're on. No more juggling four vendor portals.
- Ask in plain English. Get a cited answer in seconds.
- Read the answer next to the source PDF, with the exact passage highlighted on the right page. Verify the answer against the protocol without ever leaving the screen.
- Screen a patient against multiple trials at once.
- Flag anything that needs sponsor clarification. The sponsor sees it in their workbench.
askmytrials.com/dashboard/ask
ATD002 / Protocol v3.2
Can a patient on bimekizumab enroll?
Sponsor verifiedp. 52
No. Section 5.2 lists biologic IL-17 inhibitors as exclusionary if dosed within 12 weeks of screening. Bimekizumab is an IL-17A/F inhibitor and falls under that exclusion. A 12-week washout is required before re-screening.
Protocol_v3.2.pdf52 / 218
For CRAs and monitors
- Stop scrolling 200-page PDFs with Ctrl+F looking for the right passage.
- Ask the protocol the question you'd ask the medical monitor. Get the answer with the cited page, and confirm what the protocol actually says before you ask a site to change anything.
- Build monitoring visit checklists from the cited source, not from memory of the last version you read.
askmytrials.com/monitor/search
unscheduled visit window dosing tolerance4 results / 0.42s
7.4 Dosing schedulep. 78
An unscheduled visit window of plus or minus 48 hours is permitted for IP administration when site staffing requires it.
7.5 Missed dosep. 81
If dosing tolerance exceeds 72 hours, the dose must be skipped and recorded as a protocol deviation.
8.2 Visit windowsp. 94
All visit windows are calculated from Day 1 dosing, not from screening date.
11.3 Deviationsp. 142
Deviations from the dosing tolerance must be reported within 24 hours via the eDMS.
05 / Trust posture
Pharma-IT defensible from day one.
21 CFR Part 11
SOC 2 Type I in progress
GDPR DPA
CAIQ on request
SIG Lite on request
SHA-256 export manifest
21 CFR Part 11 controls implemented and documented. SOC 2 Type I fieldwork in progress, target Q3 2026. GDPR data-processing terms available. CAIQ and SIG Lite responses on request. Every Q&A is audit-logged. Every export carries a SHA-256 manifest.
Read the trust posture06 / Pricing
Pricing.
Pricing depends on the trial: phase, site count, document volume, and analytics tier. We size every pilot against the trial's actual envelope, not a list price.
Tell us about the trial. We'll come back with a number that fits.
Request a pilot07 / Get started